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Abstract 
Objective: The dual pathway model has been proposed to explain the heterogeneity in symptoms of 
attention-deficit/hyperactivity disorder (ADHD) by two independent psychological pathways based on 
distinct brain circuits. The authors aimed to test whether the hypothesized cognitive and motivational 
pathways had separable neural correlates. 
Method: Using a longitudinally community-based cohort of 1,963 adolescents, the neuroanatomical 
correlates of ADHD were identified by a voxel-wise association analysis, and then validated using an 
independent clinical sample (99 never-medicated patients with ADHD, 56 medicated patients with 
ADHD and 267 heathy controls). The cognitive and motivational pathways were assessed by 
neuropsychological tests of working memory (WM), intra-subject variability (ISV), stop signal reaction 
time and delay discounting (DD). The associations were tested between the identified neuroanatomical 
correlates and both the ADHD symptoms 2 years later and the polygenic risk score for ADHD.  
Results: Gray matter volumes (GMV) of both a prefrontal cluster and a posterior-occipital cluster were 
negatively associated with inattention. Compared with healthy controls, never-medicated, but not 
medicated patients had significantly lower GMVs in these two clusters. WM and ISV were associated 
with the posterior-occipital cluster while DD was independently associated with both clusters. The 
baseline GMV of the posterior-occipital cluster predicted the inattention symptoms in a 2-year follow-
up and was associated with the genetic risk for ADHD. 
Conclusions: The dual pathway model has both shared and separable neuroanatomical correlates, and 
the shared correlate in the occipital cortex has a potential to serve as an imaging trait marker of ADHD, 
especially the inattention symptom domain.  
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Introduction 
Attention-deficit/hyperactivity disorder (ADHD) is one of the most common neurodevelopmental 
disorders, affecting 5.9-7.1% children and adolescents worldwide (1), 50-66% of which persist into 
adulthood (2, 3). This disorder has been characterized by its significant heterogeneity as patients 
receiving the same diagnosis often present neuropsychological impairments in distinct domains (4). 
Therefore, identification of the neural abnormalities underlying these heterogeneous impairments may 
improve both diagnostic accuracy and treatment efficiency of this disorder. 
 
To account for such heterogeneity, a dual pathway model has suggested two separable 
psychopathophysiological pathways leading to the symptoms of ADHD (5-7), including cognitive 
dysfunctions, such as deficits in working memory (WM) (8), attention regulation (intra-subject 
variability; ISV) (9), and response inhibition (stop signal reaction time; SSRT) (10), and motivational 
dysfunction, such as preferring small immediate rewards over larger delayed rewards (delay discounting; 
DD) (11). As the frontostriatal dysfunction has been frequently associated with ADHD by neuroimaging 
studies (12), one hypothesis has been proposed that these two pathways can be dissociated into the fronto-
dorsal striatal circuit responsible for cognitive dysfunction and the fronto-ventral striatal circuit for 
motivational dysfunction (5). Previous behavioral studies have reported that children with ADHD have 
cognitive and motivational deficits (13, 14), both of which independently contribute to ADHD symptoms 
(15-17). However, it is still under debate whether the cognitive and motivational deficits are 
independent from (18, 19) or associated with each other (20, 21). Recent studies seem to suggest a 
functional overlap between these two pathways, for example, WM training could also improve DD (22, 
23). In neuroimaging studies, a large-scale brain system beyond the frontostriatal model has also been 
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discussed (24), for example, a 2016 meta-analysis reported ADHD patients with structural abnormalities 
in both the right basal ganglia/insula and prefrontal cortex, and also in the left occipital lobe (25). 
Therefore, the main goal of the current study is to test whether these two pathways are linked to ADHD 
symptoms by shared and/or separable neuroanatomical correlates.  
 
Given ADHD has been considered as an extreme of a quantitative trait (26), we first analyzed a large-
scale population-based sample to identify its neuroanatomical correlates, and then validated the findings 
using an independent clinical sample. With both never-medicated and medicated patients with ADHD in 
this clinical sample, we were also able to assess the effects of medication on these neuroanatomical 
correlates. For the first time, to our knowledge, we assessed the independent associations of the identified 
neuroanatomical correlates with both cognitive (i.e. WM, ISV, SSRT) and motivational deficits (i.e. DD) 
in one comprehensive study. To demonstrate the potential of our findings to be an intermediate phenotype 
of ADHD (27), we further tested whether the identified neuroanatomical correlates contributed to 
explaining ADHD symptoms 2 years later and whether these correlates were associated with genetic risks 





IMAGEN is a community-based longitudinal study of adolescent brain development (28). Detailed 
recruitment procedure has been published elsewhere, and written informed consents were obtained from 
all participants and their legal guardians. 1,963 participants (952 males [49%]) who had completed 
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psychometric assessments and quality controls of neuroimaging data at the baseline (i.e. at the age of 14 
years old) were included in the present study (Table 1). 
 
Clinical Cohort  
ADHD-200 is a multi-center clinical study (29) approved by the local research ethics review boards at 
each center. 233 ADHD patients (188 males; ; 129 with combined subtype, 8 
with hyperactive/impulsive subtype and 96 with inattentive subtype; 56 medicated, 99 never-medicated 
and 78 missing medication information) and 267 typically-developed controls (TD; 141 males;
) who had quality controlled MRI data were included in the present study 




The Strengths and Difficulties Questionnaire (SDQ), assessed at both baseline and follow-up in 
IMAGEN, is a validated assessment tool for mental health problems in youth (30), and has been 
demonstrated to be a promising assessment for ADHD symptoms in IMAGEN (31-34). The 
hyperactivity-inattention subscale is composed of 5 items covering 3 key symptom domains for ADHD 
with the internal consistency (Cronbach’s α=0.75) at an acceptable level (α>0.6) (35). As used in 
nationwide epidemiological studies (36), a 3-band classification was established for the SDQ using a cut-
off score of 6 ( ). We used the parent-
reported SDQ, because the parent version is more reliable than the self-reported version by the children, 
and the parent-SDQ also has a stronger association with clinical assessment (odds ratio: 32.3 vs. 5 for 
mean age 11.75 3.01= ±
mean age 11.98 3.04= ±
normal: 6,  80%;  borderline: 6,  10%;  abnormal: 6,  10%< = >
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ADHD) (30, 36). If a participant had abnormal (or normal) scores at both ages 14 and 16 years, then this 
participant was classified into the persistent (or typically-developed control) group.  
 
Delay discounting 
The Monetary Choice Questionnaire (37), which is an efficient and reliable measurement of DD and has 
been validated in adolescents (38), was assessed at baseline. It contains 27 dichotomous choice items 
pitting a smaller-immediate reward against a larger delayed reward for three levels of reward magnitude 
(i.e. small, medium, large). Higher value of k-coefficient in a hyperbolic discounting equation for each 
reward level represents greater preference for small immediate rewards and higher impulsivity (eMethod 
2). The geometric mean was calculated and logarithmically transformed to use in our analyses. 
 
Working memory 
The spatial working memory in the Cambridge Neuropsychological Testing Automated Battery (39) was 
measured at baseline. This is a self-ordered searching task to measure participants’ ability to preserve 
spatial information (40), and it is widely used in studies of ADHD in children and adolescents (41). The 
number of errors was used as an index of WM. 
 
Intra-subject variability and stop signal reaction time 
ISV and SSRT were obtained by behavioral data for the stop signal fMRI task (42) (n=1,846). ISV was 
estimated by the standard deviation of reaction time in successful GO trials. SSRT was estimated by 
subtracting the mean stop signal latency from the mean correct go response time. Participants who had 




The Magnetic Resonance Imaging (MRI) acquisition protocols and quality controls in IMAGEN have 
been described in detail (28). The high resolution T1-weighted magnetization prepared gradient echo 
sequence was collected using 3T scanners and preprocessed using the VBM8 toolbox as reported 
previously (43) (eMethod 3). 
 
Genetic data 
Genotyping was carried out from blood drawn from IMAGEN participants (28). Genotype information 
was collected at 582,982 markers using the Illumina Human Genotyping Bead Chip. After quality control, 
1,790 cases were included in our sample totaling 506,932 SNPs available for establishing the polygenic 
risk score (PRS) for ADHD (eMethod 4).  
 
Statistical analysis 
Voxel-wise brain-wide association analysis 
A whole-brain analysis was conducted at the voxel level using the general linear model in SPM12 to 
identify clusters with GMV associated with ADHD total score at the baseline in IMAGEN. Age, sex, 
handedness, total intracranial volume (TIV) and site were considered as covariates. IQ is not 
recommended to be controlled in cognitive studies of neurodevelopmental disorders, since it is often 
affected by the disorder (44). An uncorrected p<0.001 at voxel-level, with a cluster-level family-wise 
error (FWE; p<0.05) was applied to identify significant clusters (45).  
 
Neuropsychological association analysis 
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Separate partial correlation analyses were conducted between neuropsychological measures (i.e. WM, 
ISV, SSRT or DD) and both ADHD symptoms and GMV of the significant clusters, controlling for age, 
sex, handedness, TIV and site. Confidence interval was given by 5,000 bootstraps. Next, we included 
other variables as covariates for the association analysis of one variable. If a significant association 
becomes insignificant after controlling other variables, this association is not independent to other 
variables but is contributed by some common factor shared between cognitive and motivational deficits.  
 
Prospective association analysis 
We extended our analysis to ADHD symptoms at the age of 16 years in IMAGEN. Hierarchical multiple 
regression was applied to identify significant association between the baseline features and ADHD 
symptoms 2 years later. In these regression models with covariates and corresponding baseline symptoms, 
the behavioral variables and GMVs of the significant clusters were entered one-by-one. A variable was 
retained in the model when it significantly elevated the model performance (i.e. a significant ΔR2 with 
p<0.05). 
 
Analysis of covariance was performed between the persistent group and the TD control group in 
IMAGEN while controlling for the sex, handedness, TIV and site. Significance of the results were given 
by 10,000 random permutations (reported as p-perm), and validated by the comparisons between well-
matched samples (healthy controls were selected by an R package MatchIt to match the sample size with 




The latest genome-wide association meta-analysis of 20,183 patients with ADHD and 35,191 controls 
was used as the discovery dataset (47), the summary statistics were downloaded from the Psychiatric 
Genomics Consortium (http://www.med.unc.edu/pgc/results-and-downloads). The primary analyses are 
based on the threshold of p<0.50 since it maximally captures phenotypic variance (48), using the PRS 
software (PRSice; http://prsice.info/) (49). Associations of PRS with the neuropsychological variables 
were tested by partial correlation analyses while controlling for age, sex and site, while its associations 
with GMV of the significant clusters were assessed by additionally controlling for handedness and TIV. 
 
Validation 
We applied the identical preprocessing pipeline of structural neuroimaging data as used in IMAGEN to 
the ADHD-200 clinical sample. Using a mask of the significant clusters identified in IMAGEN, GMV 
of each cluster was extracted for analyses. We tested 1) whether patients with ADHD had lower GMVs 
of the significant clusters by comparing patients with controls; 2) which ADHD patient subtype had the 
lowest GMVs of the significant clusters by comparing between two ADHD subtypes 
(hyperactive/impulsive subtype was excluded because of a small sample size of 8) and controls; 3) 
whether medication had any remedial effect on the reduced GMVs of the significant clusters by group 
comparison among never-medicated patients, medicated patients, and controls. All analyses were 




In the IMAGEN cohort at the baseline (Table 1), WM, ISV and DD were positively associated with 
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ADHD symptoms, and the correlations were not confounded by each other (Table 2). There was no 
significant correlation between ADHD symptoms and SSRT (p>0.05), and therefore it was not included 
in further analyses. Greater DD rate was associated with more WM errors (r1952=0.13, p<0.001, 95% 
CI=0.08, 0.17) and increased ISV (r1835=0.09, p<0.001, 95% CI=0.04,0.13). 
 
Neuroanatomical correlates of inattention in a population-based cohort 
In IMAGEN at the baseline, we found that higher ADHD total score was associated with lower GMVs 
of two brain clusters in both the prefrontal cortex ( , 3,357 voxels;
) and the posterior-occipital cortex 
( , 1,295 voxels; ; ), 
respectively. The prefrontal cluster covered the left ventromedial prefrontal cortex, dorsal anterior 
cingulate cortex and anterior insula, while the posterior-occipital cluster was mainly in the left cuneus 
and extended to the left calcarine (Figure 1). These associations were not confounded by either data 
collection sites (Figure S1) or IQ (eResult 2). These associations became insignificant after controlling 
for the inattention score but remained significant after controlling for the hyperactivity/impulsivity score 
(the prefrontal cluster: r1949=-0.08, p<0.001, ; the posterior-occipital cluster: 
r1949=-0.07, p=0.002, ).  
 
Neuroanatomical correlates of inattention selectively associated with WM, ISV or DD 
In IMAGEN at the baseline, we found that more WM errors was associated with lower GMV of the 
posterior-occipital cluster even after controlling for ISV and DD (r1831=-0.07, p=0.005; Table 2). Similar 
to WM, increased ISV was associated with lower GMV of the posterior-occipital cluster even after 
19.5,  49.5,  3x y z= - = =
1950peak 4.29;t = - cluster-level 0.001pFWE <
1.5,  91.5,  15x y z= - = = 1950peak 4.32t = - cluster-level 0.025pFWE =
95% CI = -0.03 to -0.13
95% CI = -0.03 to -0.11
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controlling for WM and DD (r1831=-0.05, p=0.027; Table 2). Greater DD rate was associated with lower 
GMV’s of both clusters even after controlling for WM and ISV (the prefrontal cluster: r1831=-0.05, 
p=0.042; the posterior-occipital cluster: r1831=-0.05, p=0.049; Table 2). 
 
Prospective associations with inattention 2 years later 
After controlling for the corresponding ADHD symptom at age 14 years, WM and DD at age 14 years 
were selectively associated with inattention (t1505=2.35, p=0.019) and hyperactivity/impulsivity 
(t1505=2.24, p=0.025) at age 16 years, respectively. In the multivariate regression model, we found that 
both WM (t1404=2.04, ΔR2=0.002, p=0.042) and GMV of the posterior-occipital cluster (t1404=-3.55, 
ΔR2=0.005, p<0.001) at age 14 years were associated with inattention 2 years later (Table 3). 
 
Adolescents with persistent ADHD symptoms (n=29) had reduced GMVs of both the prefrontal cluster 
as compared with the typically-developed controls (n=1,278; ; 
F1,1295=6.37; p-perm=0.012; ), and the posterior-occipital cluster 
( ; F1,1295=5.12, p-perm=0.022; ; Figure S2). Significant 
results with even larger effect sizes were found using matched-group comparisons (29 vs. 58; eResult 3). 
 
Associations of neuropsychological and neuroanatomical intermediate phenotypes with 
polygenetic risk for ADHD 
In IMAGEN, we found higher PRS for ADHD was associated with higher ADHD total score at the 
baseline (r1779=0.14, p<0.001, ), more WM errors (r1779=0.07, p=0.002, 
), greater DD rate (r1779=0.06, p=0.007, ), and lower 
3 35.63 1.03 vs. 6.23 1.19 ml ml± ±
2partial eta-squared 0.005ph =
3 32.06 0.35 vs. 2.19 0.28 ml ml± ± 2 0.004ph =
95% CI 0.097 to 0.188=
95% CI 0.026 to 0.121= 95% CI 0.021 to 0.109=
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GMV of the posterior-occipital cluster only (r1777=-0.06, p=0.009, ). 
 
Validation using a clinical cohort of ADHD 
In ADHD-200, we confirmed that patients had lower GMVs in both the prefrontal 
( , F1,491=12.18, p<0.001, ; Figure 2A) and the posterior-
occipital clusters ( , F1,491=9.28, p=0.002,  Figure 2B). 
These volumetric reductions were non-significant in patients with the combined subtype (n=129) but 
only significant in patients with the inattentive subtype (n=96; the prefrontal cluster: F1,354=12.92, 
p<0.001,  the posterior-occipital cluster: F1,354=7.29, p=0.007,  Figure 2C-D).  
 
Medication effects 
In ADHD-200, we found that the TD controls (n=267) had the highest GMVs of both clusters, the 
medicated patients (n=56) had the intermediate GMVs, and the never-medicated patients (n=99) had the 
lowest GMVs. Compared with the TD controls, the never-medicated patients had significant group 
differences in both clusters (the prefrontal cluster: F1,357=12.37, p<0.001,  the posterior-
occipital cluster: F1,357=8.50, p=0.004,  Figure 2E-F). However, the group differences 
between the TD controls and the medicated patients became nonsignificant. The corresponding effect 
sizes were significantly decreased compared with that for the never-medicated patients (prefrontal cluster: 
,  
posterior-occipital cluster: -0.022,  given by 5,000 bootstraps). Therefore, 
these findings were unlikely to be explained by group differences of either demographics or symptom 
severity between the medicated and the never-medicated patients (eMethod 1; Table S3). 
95% CI 0.106 to -0.015= -
3 33.86 1.67 vs. 4.40 1.56 ml ml± ± 2 0.024ph =





2 2control vs. medicated)- control vs. never-medicated)=-( .031( 0p ph h 95% CI -0.068 to -0.004;=




To our knowledge, this is the first study to differentiate the neuroanatomical basis for the cognitive and 
motivational pathways of ADHD in a large population-based cohort of adolescents. The neuroimaging 
finding of a common neuroanatomical correlate, namely GMV of the posterior-occipital cluster, shared 
by both cognitive and motivational deficits suggests an overlapping neuroanatomical basis for the dual 
pathway model of ADHD. Intriguingly, the study has also revealed associations of GMV of this cluster 
with both future symptoms of and polygenic risk for ADHD in the population-based cohort. Compared 
with typically-developed controls, never-medicated patients with ADHD had the lowest GMV of this 
cluster and medicated patients had an intermediate GMV. These findings demonstrate that such 
neuroanatomical feature has a potential of serving as an intermediate phenotype of ADHD. 
 
The findings of the current neuroimaging study support an involvement of the visual attention network 
(VAN) and emphasize the importance of the large-effect cognitive impairment seen in previous 
behavioral studies in visual attention specifically, as compared with auditory attention (50, 51). First, 
both identified prefrontal and posterior-occipital clusters are located in VAN; and second, a prospective 
association of GMV of the posterior-occipital cluster selectively with the inattention score assessed 2 
years later. Abnormal brain activities of VAN have been associated with ADHD by functional 
neuroimaging studies (52), which is complementary to the current structural neuroimaging study. In this 
functional network, the occipital cortex interacts with the dorsal attention network to maintain visual 
attention (53) and suppress attention to irrelevant visual stimuli by a top-down modulation of the 
prefrontal cortex (54). These brain regions are also structurally wired together, particularly the inferior 
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fronto-occipital fasciculus (IFOF) is a direct pathway that connects the frontal and occipital lobes as well 
as the parietal and posterior temporal cortices (55). A 2016 meta-analysis of DTI studies on ADHD has 
reported consistent white matter differences located in the left IFOF (56), and been related to attention 
(57, 58). The hypothesis is that these regions may be modulated by dopamine activity. In addition to the 
well-known effect of dopamine on the prefrontal region (59-62), a 2018 study found the dopamine 
transporter (DAT1)-related reduction of GMV in the left posterior-occipital region may contribute to 
visual memory performance in children with ADHD (63).  
 
Our comparison between medicated and never-medicated patients with ADHD may suggest a positive 
effect of medication on gray matter atrophy in patients with ADHD. Stimulant medication for ADHD 
affects the brain in many aspects, including structure (64, 65), function (66), and neurotransmitter (67). 
Therefore, lower GMV of the identified clusters in never-medicated patients with ADHD may exclude 
one alternative explanation that lower GMV was caused secondarily by medication, while comparable 
GMV between medicated patients and TD controls suggests medication may have a remedial effect for 
ADHD on brain structure, which provides a possible neuroanatomical basis for the behavioral 
improvement in visual attention by stimulant treatment for ADHD (68).  
 
The dual pathway model of ADHD has been a very valuable model for our understanding of the 
neuropsychopathology of this disorder (5-7). Our findings do not support the independent pathways 
model (i.e. the cognitive circuit between dorsolateral prefrontal cortex and dorsal striatum, and the 
motivational circuit between orbito-frontal cortex and ventral striatum) (5) but instead demonstrate an 
interaction between cognition and motivation in ADHD. This interaction is not only supported by the 
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WM-DD and ISV-DD associations in the IMAGEN sample, but also supported by previous reports of 
both monetary incentive-enhanced cognition and cognitive biases-enhanced avoidance motivation (69). 
Our findings further suggest that this interaction may have its neural basis within the VAN, especially 
the left cuneus in the posterior occipital cortex and the hyperactivation of this region has been previously 
reported in task-based fMRI experiments (70). Its association with DD is not completely surprising given 
both the hyperactivation (71, 72) and higher GMV (73) of the posterior occipital cortex have already 
been associated with choosing delayed gain over immediate reward. Its association with the WM 
performance (i.e. 2-back accuracy) has also been observed in an fMRI experiment (74). Together, these 
findings may suggest that the dual pathways in ADHD are likely related to dysfunction of these cognitive 
and motivational processes, particularly in the visual attentional system, which supports the top-down 
selection of relevant information from the environment during goal-directed tasks (75). 
 
It has been reported in the literature even a small improvement in memory score (10%) can make a 
significant difference in school performance (76). The effect sizes of the identified neural associations 
were small to medium, partially owing to the multifactorial nature of ADHD. However, as shown in the 
results, these findings were statistically robust and empirically replicable using an independent clinical 
sample. Therefore, the findings may improve the accuracy of the diagnosis by using GMV of the 
posterior-occipital cluster as an intermediate phenotype of ADHD, especially the inattention symptoms. 
This neuroanatomical feature 1) is associated with inattention in the general population; 2) is associated 
with neuropsychological endophenotypes of ADHD; 3) is associated with genetic risk for ADHD; 4) 
contributes to the explanation of future inattention symptoms; and 5) is preserved in clinical patients with 
ADHD, and such a feature cannot be simply explained by a confounding effect of medication. These are 
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exactly the lines of evidence that are required for the identification of an intermediate phenotype of a 
mental health disorder (77). The occipital cluster develops early in life and functionally matures during 
childhood (78), and therefore may also be used as a neuroimaging biomarker of disrupted brain 
development for the early diagnosis of ADHD. As expected, we also found the ADHD-associated 
prefrontal cluster was indeed correlated with DD, which is consistent with the frontostriatal model of 
ADHD (79). However, given this prefrontal area is under significant development during adolescence 
(80) with a significant individual variation (81), it might be difficult to use GMV of this prefrontal cluster 
as an imaging trait marker for ADHD.  
 
Limitation 
As both parent and teacher ratings are needed for clinical diagnosis, our study using parent ratings may 
not have fully captured ADHD symptoms. The current study identified a common neural correlate for 
working memory, attention regulation and delay discounting, which represents particular aspects of the 
broader cognitive and motivational deficits in ADHD. However, the current study did not identify any 
significant association of response inhibition with the ADHD symptoms. Our findings are in adolescents, 
but the development and maturation of the posterior-occipital cortex are believed to be largely completed 
during childhood. Future longitudinally neuroimaging cohort of ADHD during childhood is necessary to 
confirm whether there is any abnormal development of this occipital cortex can be observed leading to 




In summary, using a comprehensive approach we revealed a common neuroanatomical correlate of both 
cognitive and motivational pathways for the development of ADHD. Given that the posterior-occipital 
region developed and matured much earlier than the previously focused prefrontal areas in the 
frontostriatal model of ADHD, these results might provide new clues to discover novel imaging markers 
for early diagnosis and pre-emptive intervention strategies for ADHD.  
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Table 1. Characteristics of the study population in the IMAGEN cohort 
 Baseline (n=1,963) 2 years’ follow-up (n=1,518) 
Male 952 (48.5%) 728 (48.0%) 
Age (year), mean ± SD 14.43±0.40 16.47±0.57 
H-I subscale on parent SDQ   
Total score 2.97±2.29 2.39±2.05 
Hyperactivity/impulsivity Score 0.70±1.05 0.47±0.87 
Inattention Score 2.27±1.65 1.92±1.57 
ADHD categories by H-I total score    
Normal a 1,690 (86.1%) 1,394 (91.8%) 
Borderline b 107 (5.5%) 64 (4.1%) 
Abnormal c 166 (8.5%) 62 (4.1%) 
Delay discounting -1.98±0.61 - 
Working memory 19.45±14.00 - 
Intra-subject variability d 119.38±30.96  
Stop signal reaction time d 186.43±61.90  
Note. H-I = hyperactivity-inattention. 
a: Individuals with H-I total score less than 6. 
b: Individuals with H-I total score equal to 6. 
c: Individuals with H-I total score greater than 6. 
d: n=1,846.  
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Table 2. Associations of neuropsychological variables with ADHD symptoms and GMV of the significant clusters 
 ADHD symptom a GMV b 
 Total score Hyperactivity/impulsivity Inattention Prefrontal cluster Posterior-occipital cluster 
 r 95% CI c r 95% CI c r 95% CI c r 95% CI c r 95% CI c 
WM d 0.19*** [0.15,0.24] 0.09*** [0.05,0.14] 0.21*** [0.16,0.25] -0.04 [-0.08,0.01] -0.08*** [-0.12,-0.03] 
DD d 0.13*** [0.08,0.17] 0.06** [0.02,0.11] 0.14*** [0.09.0.18] -0.07** [-0.11,-0.02] -0.06* [-0.10,-0.01] 
ISV e 0.14*** [0.10,0.19] 0.09*** [0.04,0.14] 0.14*** [0.10,0.19] -0.05* [-0.10,-0.01] -0.06** [-0.11,-0.01] 
WM corrected for DD and ISV 0.16*** [0.12,0.21] 0.07** [0.03,0.12] 0.18*** [0.13,0.22] -0.04 [-0.09,0.005] -0.07** [-0.11,-0.02] 
DD corrected for WM and ISV 0.10*** [0.05,0.15] 0.05* [0.001,0.10] 0.11*** [0.06,0.15] -0.05* [-0.09,-0.002] -0.05* [-0.09, -3.3e-4] 
ISV corrected for WM and DD 0.12*** [0.08,0.17] 0.08** [0.03,0.13] 0.12*** [0.07,0.16] -0.04 [-0.09,0.005] -0.05* [-0.10,-0.01] 
Note. GMV = gray matter volume. WM = working memory. DD = delay discounting. ISV = intra-subject variability. SSRT = stop signal reaction time. 
a: Adjusted for age, sex and site. 
b: Adjusted for age, sex, handedness, site and TIV. 
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c: Confidence interval was estimated by bootstrap 5,000 times. 
d: n=1,963. 
e: n=1,846. 
*, p<0.05; **, p<0.01; ***, p<0.001.
 35 
Table 3. Hierarchical multiple regression of WM, DD, ISV and GMV of the significant clusters on inattention at age 16 1 
(n=1,421) 2 
  Independent Variables R2 ΔR2 pe a βf b tf c pf d 
Step 1 Covariates Sex 0.412 0.412 <0.001 0.073 2.86 0.004 
  Handedness    0.016 0.79 0.430 
  TIV    0.010 0.375 0.708 
  Inattention at 14    0.608 28.45 <0.001 
  Site1    0.018 0.66 0.508 
  Site2    0.050 1.80 0.072 
  Site3    0.068 2.57 0.010 
  Site4    0.065 2.47 0.014 
  Site5    0.010 0.36 0.721 
  Site6    0.038 1.44 0.151 
  Site7    0.036 1.37 0.170 
Step 2 Behavior WM 0.414 0.002 0.017 0.044 2.04 0.042 
Step 3  DD 0.414 0.000 0.593 0.007 0.35 0.724 
Step 4  IRV 0.415 0.001 0.164 0.028 1.31 0.190 
Step 5 Brain structure GMV in prefrontal 0.415 0.000 0.685 0.047 1.88 0.060 
Step 6  GMV in posterior-occipital 0.42 0.005 <0.001 -0.083 -3.55 <0.001 
Note. WM = working memory. DD = delay discounting. ISV = intra-subject variability. GMV = gray matter volume.  3 
a: p value of ΔR2.  4 
b: standardized β in the final model. 5 
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c: t value of the regression coefficient in the final model. 6 
d: p value of the regression coefficient in the final model. 7 
  8 
 37 
 9 
Figure 1. Significant brain clusters associated with ADHD total score in a population-based cohort.  10 
The results were given by a voxel-wise whole brain analysis using the IMAGEN cohort at the age of 14 11 
years (n=1,963). Age, sex, handedness, TIV and site were used as covariates. An uncorrected p<0.001 at 12 
voxel-level, with a cluster-level family-wise error (FWE; p<0.05) was applied to identify significant 13 
clusters. Two clusters were found negatively associated with ADHD total score: the prefrontal cluster 14 
(x=-19.5, y=49.5, z=3, 3,357 voxels; peak t1950=-4.29, cluster-level pFWE<0.001), and the posterior-15 
occipital cortex (x=-1.5, y=91.5, z=15, 1,295 voxels; peak t1950=-4.32, cluster-level pFWE=0.025). No 16 
clusters were found positively associated with ADHD total score. 17 
  18 
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 19 
Figure 2. Group comparison of gray matter volume of the identified clusters in a clinical cohort.  20 
The results were based on the ADHD-200 cohort. Y axis was the residual of gray matter volume (GMV) 21 
of the identified clusters regressed on age, sex, handedness, TIV and site. A. Difference of GMV of the 22 
prefrontal cluster between controls (n=267) and ADHD patients (n=233). B. Difference of GMV of the 23 
posterior-occipital cluster between controls (n=267) and ADHD patients (n=233). C. Difference of GMV 24 
 39 
of the prefrontal cluster among controls (n=267), ADHD with combined subtype (n=129) and ADHD 25 
with inattentive subtype (n=96). D. Difference of GMV of the posterior-occipital cluster among controls 26 
(n=267), ADHD with combined subtype (n=129) and ADHD with inattentive subtype (n=96). E. 27 
Difference of GMV of the prefrontal cluster among controls (n=267), medicated patients (n=56) and 28 
never-medicated patients (n=99). F. Difference of GMV of the posterior-occipital cluster among controls 29 
(n=267), medicated patients (n=56) and never-medicated patients (n=99). Bottom and top of the box are 30 
the minimum and maximum, and the band near the middle of the box is the median. **, p<0.01; ***, 31 
p<0.001. 32 
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